Inhibrx Biosciences (INBX) Times Interest Earned (2023 - 2026)

Inhibrx Biosciences (INBX) posted quarterly Times Interest Earned of -$9.68 for Q4 2025, down 128.67% quarter-over-quarter from -$4.23 in Q3 2025.

Analysis

Inhibrx Biosciences (INBX) Times Interest Earned (2023 - 2026) Analysis & Trends

Inhibrx Biosciences (INBX) has reported Times Interest Earned for 3 consecutive years, with -$9.68 the latest figure, recorded in Q4 2025.

In Q4 2025, Times Interest Earned changed N/A year-over-year to -$9.68; the TTM figure through Dec 2025 stood at -$15.71 (up 35.88% YoY), while the FY2025 annual figure was -$0.61, up 95.97% from the prior year.
Times Interest Earned retreated to -$9.68 in Q4 2025 per INBX's latest filing, from -$4.23 in the prior quarter.
Across five years, Times Interest Earned topped out at -$3.15 in Q2 2025 and bottomed at -$29.8 in Q2 2024.
Historically, Times Interest Earned has averaged -$11.08 across 3 years, with a median of -$5.62 in 2023.
Annual changes were most pronounced in 2024 — Times Interest Earned tumbled 469.77% — and 2025, when it jumped 89.43%.
Inhibrx Biosciences' Times Interest Earned stood at -$28.32 in 2023, then decreased by 5.19% to -$29.8 in 2024, then soared by 67.53% to -$9.68 in 2025.
Business Quant data shows INBX's Times Interest Earned at -$9.68 in Q4 2025, -$4.23 in Q3 2025, and -$3.15 in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	117.59
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-493.00
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-21.24
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	8.18
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	2.82
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	1.42
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.08
10	Inhibrx Biosciences	1.91 Bn	1.91 Bn	-	-5.65

Historic Data

Download Data